These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. A new mouse model of experimental melanoma for vaccine and lymphokine therapy. Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134 [TBL] [Abstract][Full Text] [Related]
9. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Kim TS; Russell SJ; Collins MK; Cohen EP Int J Cancer; 1992 May; 51(2):283-9. PubMed ID: 1533203 [TBL] [Abstract][Full Text] [Related]
10. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036 [TBL] [Abstract][Full Text] [Related]
11. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Maruyama H; Zaloudik J; Li W; Sperlagh M; Koido T; Somasundaram R; Scheck S; Prewett M; Herlyn D Cancer Immunol Immunother; 2000 Jun; 49(3):123-32. PubMed ID: 10881691 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy. Cho D; Kim TG; Lee W; Hwang YI; Cho HI; Han H; Kwon O; Kim D; Park H; Houh D J Invest Dermatol; 2000 May; 114(5):928-34. PubMed ID: 10771473 [TBL] [Abstract][Full Text] [Related]
13. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
14. Induction of cell-mediated immunity against B16-BL6 melanoma in mice vaccinated with cells modified by hydrostatic pressure and chemical crosslinking. Eisenthal A; Ramakrishna V; Skornick Y; Shinitzky M Cancer Immunol Immunother; 1993 May; 36(5):300-6. PubMed ID: 8477416 [TBL] [Abstract][Full Text] [Related]
15. Serological characterization of a shared melanoma-associated antigen of mouse melanomas: relationship to the B700 glycoprotein. DeLeo AB; Hearing VJ; Vieira WD; Law LW Melanoma Res; 1991; 1(2):133-40. PubMed ID: 1668533 [TBL] [Abstract][Full Text] [Related]
16. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury]. Tan XH; Wan YH Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524 [TBL] [Abstract][Full Text] [Related]
17. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma. Kim TS; Russell SJ; Collins MK; Cohen EP Int J Cancer; 1993 Nov; 55(5):865-72. PubMed ID: 8244584 [TBL] [Abstract][Full Text] [Related]
18. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma. Alonso DF; Gabri MR; Guthmann MD; Fainboim L; Gomez DE Int J Oncol; 1999 Jul; 15(1):59-66. PubMed ID: 10375594 [TBL] [Abstract][Full Text] [Related]
19. MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens. Kim TS; Cohen EP Cancer Immunol Immunother; 1994 Mar; 38(3):185-93. PubMed ID: 8124687 [TBL] [Abstract][Full Text] [Related]